PIKfyve inhibitors against SARS-CoV-2 and its variants including Omicron  

作　　者：Jingyi Su Jing Zheng Wei Huang Yali Zhang Cairui Lv Baoding Zhang Lina Jiang Tong Cheng Quan Yuan Ningshao Xia Jianming Zhang Li Li Li Li Xianming Deng 

机构地区：[1]State Key Laboratory of Cellular Stress Biology,Innovation Center for Cell Signaling Network,School of Life Sciences,Xiamen University,361102 Xiamen,Fujian,China [2]Xiamen Center for Disease Control and Prevention,361021 Xiamen,Fujian,China [3]State Key laboratory of Molecular Vaccinology and Molecular Diagnostics,National Institute of Diagnostics and Vaccine Development in Infectious Diseases,School of Public Health,Xiamen University,361102 Xiamen,Fujian,China [4]National Translational Research Center,Ruijin Hospital,Shanghai Jiaotong University School of Medicine,Shanghai,China

出　　处：《Signal Transduction and Targeted Therapy》2022年第6期1885-1887,共3页信号转导与靶向治疗（英文）

基　　金：supported by grants from the National Key R&D Program and the National Natural Science Foundation of China(No.2017YFA0504504,22025702,82021003,91853203,82151211 to X.Deng,and 82073874 to L.Li);the Fundamental Research Funds for the Central Universities of China(No.20720200008 to X.Deng);Health Science and Technology Program of Fujian Province(No.2020CXB050 to J.Zheng);the Program of Introducing Talents of Discipline to Universities(111 Project,B06016).

摘　　要：Dear Editor,COVID-19 pandemic,caused by SARS-CoV-2 infection,is raging around the world and results in millions of deaths since the end of 2019.Although various therapies including vaccines and neutralizing antibodies have been developed to defend against the horrible pandemic,current strategies are inevitably at risk of failure due to high mutagenicity of the viral genome.In fact,the most worrying situation is that the monoclonal antibodies of existing vaccines against the rapidly spreading Omicron variant are ineffective.

关 键 词：OMI NEUTRAL WORRY 

分 类 号：R51[医药卫生—内科学]